Intensive care unit outcomes and prognostic factors of esophageal cancer: A cross-sectional study in Chinese cancer-specialized hospitals

Table 2 Cox regression analysis of predictors for 90 days survival of intensive care unit admitted esophageal cancer patients

Variables, demographics	Univariate analysis1		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	1.03 (0.99-1.07)	0.213
Gender
Female	Ref
Male	1.68 (0.74-3.80)	0.213
BMI (kg/m2)	0.86 (0.77-0.95)	0.002a
Treatment history
Target therapy	2.53 (0.78-8.22)	0.122
Immunotherapy	2.22 (1.06-4.67)	0.035a
Chemotherapy	1.22 (0.63-2.37)	0.554
Radiotherapy	2.38 (1.05-5.38)	0.037a
Severity scores
SOFA	1.18 (1.09-1.27)	< 0.001a	1.09 (0.98-1.20)	0.0991
APACHE II	1.13 (1.08-1.17)	< 0.001a	1.09 (1.03-1.16)	0.0031
Fourth degree myelosuppression	3.84 (1.82-8.07)	< 0.001a	3.37 (1.15-9.90)	0.0271
Anti-infection treatment
Carbapenems	3.19 (1.68-6.05)	< 0.001a
β-lactam	0.94 (0.50-1.75)	0.836
Glycopeptides	1.50 (0.69-3.26)	0.302
Tigecycline	2.46 (0.34-17.95)	0.374
Echinocandins	4.87 (1.90-12.47)	< 0.001a
Triazoles	2.58 (1.14-5.84)	0.023a
Other treatment
Mechanical ventilation	1.88 (0.95-3.69)	0.068
Conventional oxygen therapy	4.14 (1.00-17.19)	0.051
Sedation treatment	0.10 (0.05-0.19)	< 0.001a

^aP < 0.05.

¹Adjusted to age, gender, body mass index, history of immunotherapy, history of radiotherapy, mechanical ventilation, sedation treatment, conventional oxygen therapy, use of carbapenems, echinocandins and triazoles.

HR: Hazard ratio; CI: Confidence interval; BMI: Bosy mass index; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology and Chronic Health Evaluation II.